Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
EBIATLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsPreferred Shares IssuedReceivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Opus Genetics (IRD) Shares Outstanding (2019 - 2026)

Opus Genetics has reported Shares Outstanding over the past 13 years, most recently at $71.4 million for Q1 2026.

  • Quarterly Shares Outstanding rose 56.98% to $71.4 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $71.4 million through Mar 2026, up 56.98% year-over-year, with the annual reading at $69.9 million for FY2025, 121.36% up from the prior year.
  • Shares Outstanding was $71.4 million for Q1 2026 at Opus Genetics, up from $69.9 million in the prior quarter.
  • Over five years, Shares Outstanding peaked at $71.4 million in Q1 2026 and troughed at $19.2 million in Q1 2022.
  • The 5-year median for Shares Outstanding is $25.1 million (2024), against an average of $34.7 million.
  • Year-over-year, Shares Outstanding increased 4.41% in 2023 and then skyrocketed 146.37% in 2025.
  • A 5-year view of Shares Outstanding shows it stood at $20.9 million in 2022, then increased by 14.94% to $24.0 million in 2023, then skyrocketed by 31.68% to $31.6 million in 2024, then skyrocketed by 121.36% to $69.9 million in 2025, then grew by 2.16% to $71.4 million in 2026.
  • Per Business Quant, the three most recent readings for IRD's Shares Outstanding are $71.4 million (Q1 2026), $69.9 million (Q4 2025), and $64.5 million (Q3 2025).